|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The apoptosis- 1/Fas protein in human systemic lupus erythematosus 显示文摘 | Mysler E Bini P Drappa J | 1994 | J Clin Invest1994，93，3： | 1 |
| 2 | Efficacy and safety of ocrelizumab in active proliferative lupus nephritis:Results from a randomized,double-blind,phase Ⅲ study显示文摘 | Mysler EF Spindler AJ Guzman R | | 0，，： | 1 |
| 3 | Canakinumab reducesthe risk of acute gouty arthritis flares during initiation ofallopurinol treatment: results of a double-blind,randomisedstudy 显示文摘 | Schlesinger N Mysler E Lin HY | 2011 | Ann Rheum Dis2011，70，7： | 1 |
| 4 | Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study显示文摘 | Eduardo F. Mysler Alberto J. Spindler Renato Guzman Marc Bijl David Jayne Richard A. Furie Frédéric A. Houssiau Jorn Drappa David Close Romeo Maciuca Kajal Rao Saba Shahdad Paul Brunetta | 2013 | Arthritis & Rheumatism2013，，： | 1 |
| 5 | Canakinumab reducesthe risk of acute gouty arthritis flares during initiation ofallopurinol treatment: results of a double-blind, randomisedstudy 显示文摘 | Schlesinger N Mysler E Lin HY | 2011 | Arm Rheum Dis2011，70，7： | 1 |
| 6 | Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET),reduction in ulcer complications:randomised controlled trial显示文摘 | Schnitzer TJ Burmester GR Mysler E | 2004 | Lancet2004，364，： | 1 |
| 7 | Canakinumab reduces therisk of acute gouty arthritis flares during initiation of allopurinol treat-ment: results of a double-blind, randomised study显示文摘 | Schlesinger N Mysler E Lin HY | 2011 | Ann Rheum Dis2011，70，7： | 1 |
| 8 | Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications : randomised controlled trial显示文摘 | Schnitzer TJ Burmester GR Mysler E et al | 2004 | Lancet2004，364，66： | 1 |
| 9 | Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study显示文摘 | Schlesinger N Mysler E Lin H Y | 2011 | Ann Rheum Dis2011，70，12： | 1 |
| 10 | Theapoptosis-1/Fas protein in human systemic lupus erythematosus显示文摘 | Mysler E Bini P Drappa J | 1994 | J ClinInvest1994，93，： | 1 |
| 11 | The apoptosis-1/Fas protein in human systemic lupus erythematosus 显示文摘 | Mysler E Koch N Mundel P | 1994 | J Clin Invest1994，93，： | 1 |
| 12 | Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment:results of a double-blind,randomised study显示文摘 | Schlesinger N Mysler E Lin HY | 2011 | Ann Rheum Dis2011，70，7： | 1 |
| 13 | The apoptosis-1/Fas protein in human systemic lupus erythematosus显示文摘 | Mysler E Bini P Drappa J | 1994 | J Clin Invest1994，93，3： | 1 |
| 14 | Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TAR- GET), reduction in ulcer complications: randomised controlled trial显示文摘 | SCHNITZER TJ BURMESTER GR MYSLER E | 2004 | Lancet2004，364，9435： | 1 |
| 15 | The apoptosis-1/Fas protein in human systemic lupus erythematosus显示文摘 | Mysler E Bini P Drappa J | 1994 | J Clin Invest1994，93，3： | 1 |
| 16 | The apoptosis-1/Fas protein in human systemic lupusErythematosus显示文摘 | Mysler E Bini P Drappa J | 1994 | J Clin Invest1994，93，3： | 1 |
| 17 | Efficacy and Safety of Ocrelizumab, a Humanized antiCD20 Antibody, in Patients with Active Proliferative Lupus Nephritis (LN): Results from the Randomized, Double - Blind Phase III BELONG Study显示文摘 | Mysler Eduardo F Spindler | 2010 | Arthritis Rheum2010，62，10： | 1 |
| 18 | Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study显示文摘 | Mysler EF Spindler AJ Guzman R | 2013 | Arthri- tis Rheum2013，65，9： | 1 |
| 19 | Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from arandomized, double-blind, phase W study 显示文摘 | Mysler EF Spindler A J Guzman R | 2013 | Arthritis Rheum2013，65，9： | 1 |
| 20 | Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET),reduction in ulcer complications:randomised controlled trial显示文摘 | SCHNITZER T J BURMESTER G R MYSLER E | 2004 | Lancet2004，364，9435： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员